Collecting duct carcinoma

Summary

Collecting duct carcinoma (MONDO:0005220) is a cancer and 11 clinical trials. Molecularly, BRAF D594N AND BRAF G466A confers sensitivity to Cetuximab in Collecting Duct Carcinoma (CIViC Level D); 1 further subtype–drug associations are mapped below. Top therapeutic interventions include cabozantinib, bevacizumab, and enfortumab vedotin. A subtype of renal cell carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• Clinical trials: 11
• Precision-medicine evidence (CIViC): 2 subtype–drug associations

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	collecting duct carcinoma
Mondo ID	MONDO:0005220
EFO	EFO:0003016
Orphanet	247203
DOID	DOID:4464
ICD-11	1481495173
NCIT	C6194
UMLS	C1266044
MedGen	266092
GARD	0009573
Anatomy (UBERON)	UBERON:0001232
Is cancer (heuristic)	yes

Also known as: BDC · Bellini carcinoma · Bellini duct carcinoma · Bellini’s duct carcinoma · carcinoma of collecting duct of renal tubule · carcinoma of collecting ducts of Bellini · carcinoma of kidney collecting duct · carcinoma of renal collecting duct · carcinoma of the collecting ducts of Bellini · carcinoma of the kidney collecting duct · carcinoma of the renal collecting duct · CDC · cDC · collecting duct carcinoma · collecting duct carcinoma of the kidney · collecting duct of renal tubule carcinoma · collecting duct renal cancer · collecting duct renal cell carcinoma · kidney collecting duct carcinoma · renal carcinoma, collecting duct type (+1 more)

Data availability: 2 cell lines.

Disease family

This is a subtype of renal cell carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › renal cell carcinoma › collecting duct carcinoma

Related subtypes (10): mucinous tubular and spindle renal cell carcinoma, renal pelvis adenocarcinoma, Wolffian duct adenocarcinoma, renal cell adenocarcinoma, cystic renal cell carcinoma, kidney medullary carcinoma, adrenal cortex carcinoma, nonpapillary renal cell carcinoma, MIT family translocation renal cell carcinoma, acquired cystic disease-associated renal cell carcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated or in trials for this disease

4 approved drugs — disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Status
Axitinib	Approved (phase 4)
Bevacizumab	Approved (phase 4)
Pembrolizumab	Approved (phase 4)
Cabozantinib	Approved (phase 3)

Clinical trials & evidence

Clinical trials

Clinical trials: 11.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	10
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03635892	PHASE2	ACTIVE_NOT_RECRUITING	A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma
NCT03866382	PHASE2	RECRUITING	Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT04071223	PHASE2	ACTIVE_NOT_RECRUITING	Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study
NCT04413123	PHASE2	ACTIVE_NOT_RECRUITING	Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCC
NCT06211114	PHASE2	RECRUITING	Study to Evaluate the Efficacy and Safety of Immunotherapy With Axitinib in Advanced Collecting Duct Carcinoma
NCT06302569	PHASE2	RECRUITING	Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma
NCT01767636	PHASE2	COMPLETED	Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer
NCT02363751	PHASE2	COMPLETED	Study of Gemcitabine+Platinum Salt+Bevacizumab Combination for Metastatic Collecting Duct Carcinoma (GETUG-AFU 24)
NCT03354884	PHASE2	COMPLETED	caBozantinib in cOllectiNg ductS Renal Cell cArcInoma
NCT04603365	PHASE2	WITHDRAWN	Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
NCT05372302	Not specified	UNKNOWN	Collecting Ducts Carcinoma: in Depth Exploration and Biologically Driven Therapy (CICERONE)

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CABOZANTINIB	4	5
BEVACIZUMAB	4	1
ENFORTUMAB VEDOTIN	4	1
PAZOPANIB HYDROCHLORIDE	4	1
RADIUM RA 223 DICHLORIDE	4	1
PAMIPARIB	3	1
CHEMBL4215501	0	2
CHEMBL4849721	0	2
EXELIXIS	0	2
CHEMBL3919533	0	1

Precision-medicine subtype map (CIViC)

Drug × molecular subtype: 2 predictive associations from 2 curated evidence items.

Molecular subtype	Therapy	Effect	Level	CIViC
BRAF D594N AND BRAF G466A	Cetuximab	Sensitivity/Response	CIViC D	EID12448
BRAF D594N AND BRAF G466A	Capmatinib + Crizotinib	Sensitivity/Response	CIViC D	EID12449